# Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

> **NCT06133062** · PHASE2 · RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **RADIATION:** Proton radiotherapy

## Key facts

- **NCT ID:** NCT06133062
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-16
- **Primary completion:** 2028-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06133062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06133062, "Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06133062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*